Hypertension Management with Angiotensin Receptor Blockers

Introduction to Angiotensin Receptor Blocker Dosing

The American College of Cardiology recommends a target dose of 160 mg twice daily (320 mg total daily dose) for valsartan, with doses adjusted no more frequently than every 2 weeks to target doses or maximally tolerated doses, and at minimum, patients should achieve at least 50% of the target dose (160 mg daily or 80 mg twice daily) 1
The American College of Cardiology also recommends losartan 100 mg once daily for optimal blood pressure control, providing effective 24-hour coverage while promoting medication adherence, with a target dose of 100 mg daily for losartan, as supported by the 2020 ACC/AHA guidelines 1, 1

The European Society of Cardiology notes that the most dramatic decreases in blood pressure typically occur with the initial dose, with subsequent dosing increments causing comparatively smaller changes, and many physicians underutilize target doses of ARBs in heart failure patients, with <25% of patients ever reaching target doses in clinical practice 2
The target dose of valsartan for heart failure (160 mg twice daily) is higher than typically used for hypertension, according to the European Journal of Heart Failure 2
Higher doses (150 mg) of losartan provide greater clinical benefit than lower doses (50 mg), as demonstrated by the HEAAL trial, with moderate strength of evidence 3, 4, 3
For patients with stage 2 hypertension, the American College of Cardiology recommends consideration of initiating treatment with 2 antihypertensive agents of different classes, and alternative options for combination therapy include adding a thiazide-like diuretic, beta-blocker, or mineralocorticoid receptor antagonist, as supported by the European Society of Cardiology and the American Heart Association 5, 6, 7, 8

In patients with nephropathy in Type 2 diabetes, losartan can be started at 50 mg once daily, with increase to 100 mg once daily based on blood pressure response 9
Black patients may respond better to a combination of ARB + dihydropyridine CCB or ARB + thiazide diuretic, and the ARB + CCB combination is particularly beneficial for patients with diabetes or chronic kidney disease (CKD) 10, 8
For patients with heart failure and reduced ejection fraction who cannot tolerate ACE inhibitors, losartan is recommended as a first-line alternative, particularly those with left ventricular systolic dysfunction (LVEF ≤40%), according to the European Society of Cardiology and American Heart Association 3, 11, 6, 12

The target blood pressure is <140/90 mmHg, with a goal to reduce blood pressure by at least 20/10 mmHg, as recommended by the International Society of Hypertension and the American Heart Association 10
Blood pressure readings of ≥160/100 mmHg are classified as Grade 2 hypertension, according to the International Society of Hypertension guidelines 10
Target blood pressure should be individualized based on frailty status, but generally aim for <140/90 mmHg if tolerated, with rechecking of BP in 1 month for stage 1 hypertension with 10-year ASCVD risk ≥10%, and evaluation within 1 month of diagnosis for stage 2 hypertension, as recommended by the American Heart Association 13, 14

For resistant hypertension, consider adding spironolactone 25 mg daily if serum potassium is <4.5 mmol/L, or alternatives such as eplerenone, amiloride, beta-blocker, or alpha-blocker if spironolactone is not tolerated, as recommended by the American Heart Association and the European Society of Cardiology 8
Medication adherence should be verified at each visit, and once-daily dosing and single-pill combinations should be considered to improve adherence, as recommended by the International Society of Hypertension 10
Renal function and potassium levels should be monitored, especially in patients with chronic kidney disease, bilateral renal artery stenosis, or concomitant potassium-sparing diuretics, as advised by the European Society of Cardiology 7, 15, 16
Temporary side effects like mild dizziness upon standing can often be managed through patient education rather than dose reduction 17

Underdosing in heart failure patients is common, as many clinicians fail to titrate to target doses, which may result in suboptimal outcomes, and failing to recognize that valsartan requires higher doses for heart failure (160 mg twice daily) than for hypertension (80-320 mg once daily) can lead to inadequate treatment 2
Permanent dose reductions after temporary adverse effects should be avoided, as in clinical trials, 40% of patients who required temporary dose reduction were subsequently restored to target doses 2